Abstract-Hypertension-induced diastolic heart failure accounts for a large proportion of all heart failure presentations.
H ypertension induces left ventricular (LV) hypertrophy (LVH) and is a major cause of both diastolic and systolic heart failures (HF). 1 Diastolic HF accounts for up to Յ50% of all HF presentations 2 and is associated with increasing morbidity and mortality. 3 Diastolic HF refers to the clinical syndrome of pulmonary congestion in the presence of a normal LV ejection fraction, whereas diastolic dysfunction denotes an abnormality of mechanical properties that exist during LV relaxation and filling. 4, 5 Diastolic dysfunction may be an intermediary between hypertension and HF. 6 In the setting of hypertension, diastolic HF represents a diverse clinical syndrome with various associated comorbidities (eg, age and sex) and manifests a spectrum of symptoms ranging from exercise intolerance to acute pulmonary edema. In addition to LVH, cardiac fibrosis, altered myocyte calcium handling, 7 and ventricular-vascular stiffening plays a significant role in the pathophysiology of diastolic HF. 7 In the African-American Heart Failure Trial (AHeFT), fixed-dose isosorbide dinitrate and hydralazine (HISDN) reduced mortality in black patients with advanced systolic HF. 8, 9 The predominant cause of HF in AHeFT was hypertension. 9 Benefits of HISDN are partially derived from nitric oxide (NO), 10 which results in vasorelaxation, inhibition of cardiac hypertrophy, 11 and improved cardiac remodeling. [11] [12] [13] Unfortunately the use of NO donors is limited by the development of tolerance. With HISDN, the component of hydralazine (a potent antioxidant) is thought to diminish NO consumption by reactive oxygen species 14, 15 and reactive nitrogen species. 16 The survival benefits seen in AHeFT were reported to be attributed to myocardial effects, because LV ejection fraction improved, and LV mass was reduced. 17 However, there are no experimental studies thus far that test this hypothesis. We, therefore, sought to test the hypothesis that chronic fixed-dose HISDN modulates LVH and adverse myocardial remodeling in hypertension-induced diastolic HF.
Methods and Materials
An expanded Materials and Methods section is available in the online Data Supplement at http://hyper.ahajournals.org. Ten-weekold male FVB mice (Charles River) were maintained on a 12-hour light/dark cycle in a temperature-controlled (19°C to 21°C) room. Mice were fed standard rodent chow ad libitum. The Boston University School of Medicine Institutional Animal Care and Use Committee approved all of the study procedures related to handling and surgery of the mice.
Results

HISDN Improved Hypertension But Had No Effect on Cardiac Hypertrophy
All of the mice survived (Table 1) . HISDN prevented the aldosterone-induced increase in systolic blood pressure (SBP; 137Ϯ5 versus 161Ϯ3 mm Hg; PϽ0.001). Heart rate tended to be lower with aldosterone infusion but was unaffected by HISDN. The body weight (BW) of all of the HISDN-treated mice was increased; therefore, morphological measurements were normalized to BW. This was attributed to the HISDNchow being made with lactose. Aldosterone caused LVH, as shown by an increase in the LV weight:BW ratio (4.2Ϯ0.1). However, despite the reduction in SBP in aldosterone-HISDN mice, there was no decrease in the LV weight:BW ratio. Cardiomyocyte cross-sectional area was increased in response to aldosterone infusion. Similar to the LV weight:BW ratio, cardiomyocyte hypertrophy was no different between aldosterone-untreated and aldosterone-HISDN hearts. Aldosterone infusion induced pulmonary congestion that was unaffected by HISDN.
HISDN Had No Effect on Cardiac Structure and Systolic Function
Aldosterone infusion increased LV end-diastolic dimensions but not end-systolic dimensions. LV end-diastolic dimensions and LV end-systolic dimensions were unaltered by HISDN ( Figure 1A and 1B). LV fractional shortening was unchanged and not different between aldosterone-untreated and aldosterone-HISDN hearts ( Figure 1C ). Consistent with LVH and cardiomyocyte hypertrophy, total wall thickness was increased with aldosterone and unaffected by HISDN ( Figure  1D and Table 1 ).
HISDN Improved Diastolic Dysfunction
Aldosterone infusion induced diastolic HF (normal LV systolic function and pulmonary congestion; Table 2 ). 18 Mitral valve inflow velocity was determined by Doppler echocardiography. Measurements were standardized at a lower and comparable heart rate in all of the groups to control for loading. 19, 20 The normal physiological heart rate in mice is rapid (Ͼ600 bpm) and results in the loss of the A velocity. 19, 20 Aldosterone increased the mitral E velocity (early diastolic filling velocity) with minimal change in late diastolic filling (mitral A wave). The resultant E/A ratio (diastolic dysfunction) was, therefore, increased, indicating reduced LV compliance (increased stiffness). Consistent with the elevated E/A ratio, the isovolumetric contraction time was increased, whereas deceleration time tended to shorten with aldosterone infusion. HISDN treatment significantly decreased mitral E velocity and increased the mitral A wave ( Table 2) . As a result, the E/A ratio was decreased, indicating a more compliant LV. HISDN shortened both deceleration time and isovolumetric contraction time, indicating improved LV relaxation and compliance ( Figure 1E ). HISDN improved diastolic function, although "clinical" evidence of pulmonary congestion was unaltered (Table 1) .
HISDN Had No Effect on Cardiac Fibrosis and Cytokine Expression
To determine whether the improvement in diastolic dysfunction was associated with a reduction in cardiac fibrosis, both interstitial and perivascular fibrosis were measured. Total fibrosis (interstitial and perivascular fibrosis) was increased in both groups of aldosterone-infused mice but was not different between aldosterone-untreated and aldosterone-HISDN hearts by quantitative analysis (Figure 2A and 2B) .
Aldosterone also induces a proinflammatory response. 21 Macrophage infiltration by ED-1 staining was measured and shown to be present in the interstitial areas of the LV. HISDN did not alter ED-1 staining ( Figure 3A ). Myocardial cytokine mRNA levels and quantitative RT-PCR were performed with specific primer sets with normalization to GAPDH. Aldosterone infusion increased LV interferon-␥ expression 2.6-fold (PϽ0.05), interleukin (IL) 6 expression 2.8-fold (PϽ0.05), and tumor necrosis factor (TNF)-␣ expression 1.8-fold (PϽ0.01) compared with saline infusion (Figure 3B through 3E). HISDN decreased interferon-␥ and IL-6 transcripts (PϽ0.05 versus aldosterone untreated) with no effect on TNF-␣ expression. LV IL-1␤ expression was negligibly altered by aldosterone infusion or therapy with HISDN ( Figure 3E ).
HISDN and Fetal Gene Re-Expression
Aldosterone infusion increased myocardial atrial natriuretic peptide (ANP) mRNA expression by Ϸ2.0-fold (PϽ0.05 versus saline infusion) and had negligible effects on SERCA2 mRNA expression. Both ANP and sarcoplasmic reticulum Ca 2ϩ -ATPase (SERCA2) transcripts were decreased significantly in aldosterone-HISDN hearts (PϽ0.05 and PϽ0.001, respectively, versus aldosterone untreated; Figure 4A through 4B).
HISDN Improved Exercise Capacity
Exercise limitation occurs in human diastolic HF, 22 and "quality-of-life" scores were improved in AHeFT with HISDN therapy. 23 We sought to determine whether diastolic dysfunction improvement was associated with improved functional outcome by measuring exercise capacity in these mice. Exercise capacity (determined by running distance) was measured in a blinded manner. There were no differences between the saline-untreated and saline-HISDN groups (Figure 5A ). Exercise capacity was impaired in aldosteroneuntreated mice (PϽ0.05 versus saline infusion). HISDN improved exercise capacity by Ϸ40% in aldosterone-infused mice (PϽ0.05 versus aldosterone untreated). Running time was also increased in aldosterone-HISDN (999Ϯ68 seconds) versus aldosterone-untreated (776Ϯ47 seconds; PϽ0.05) mice.
HISDN Improved Vascular Inflammation
Plasma soluble vascular cell adhesion molecule (sVCAM-1; a marker of vascular inflammation) was increased in hypertensive, untreated mice with diastolic HF (PϽ0.01 versus saline infusion). Therapy with HISDN decreased sVCAM-1 levels in aldosterone-infused mice (PϽ0.05 versus aldosterone untreated; Figure 5B ).
Discussion
In this study, aldosterone-induced hypertension resulted in LVH, diastolic dysfunction, and diastolic HF. Fixed-dose HISDN lowered SBP and improved diastolic dysfunction and exercise capacity. It also decreased plasma sVCAM-1 (a marker of vascular inflammation) and myocardial interferon-␥ and IL-6 expression. HISDN did not ameliorate LVH or cardiomyocyte size. Similarly pulmonary congestion and cardiac fibrosis remained unaffected.
HISDN and Exercise
Exercise intolerance is seen in diastolic HF, 22 ; therefore, exercise capacity was determined in the mice. The improved exercise capacity seen in our study may be because of the following: (1) a reduction in SBP despite the presence of LVH; (2) an improvement in diastolic dysfunction 24 ; and (3) a decrease in vascular inflammation/stiffness. Although not directly addressed in our study, the effect of HISDN was not limited to the myocardium. Vascular-ventricular stiffening during exercise (or other stressors) may lead to an exaggerated hypertensive response and further load-dependent diastolic dysfunction. 25 Therefore, it is possible that HISDN enhanced vascular and ventricular interactions (that affect LV filling and ejection) and, thus, improved diastolic dysfunction and exercise capacity.
HISDN and Diastolic Dysfunction
Diastolic dysfunction is an independent risk factor for HF and cardiovascular death. 26, 27 If diastolic dysfunction is considered a "preclinical" diagnosis, its early recognition may represent an important way to reduce the incidence of congestive HF. 28 Conversely, diastolic dysfunction may also be an early marker of cardiac end-organ damage in hypertension that precedes the development of LVH. 6 The presence of hypertension also increases afterload and decreases early diastolic filling and myocardial lengthening. 29, 30 Increased preload and afterload affect the LV relaxation rate, and these become more pronounced during neurohormonal stimulation (eg, aldosterone infusion or during exercise), which then further exacerbates diastolic dysfunction. In our study, SBP reduction improved diastolic dysfunction and exercise capacity. In humans, diastolic dysfunction need not be present to meet the definition of diastolic HF. 31 Similarly, diastolic dysfunction may herald the development of diastolic HF 26, 27 or systolic HF. 28 We cannot exclude the possibility that, if mice were followed for a longer period, improvement in diastolic dysfunction may precede potential decreases in pulmonary congestion (ie, diastolic HF) with HISDN therapy. Thus, recognition of the beneficial effects of HISDN on Doppler diastolic indices and exercise capacity may potentially translate into relief of pulmonary congestion because of vasodilatory effects of HISDN on the vasculature. 14,15 Characterizing LV diastolic properties in humans is usually done by measuring pressure and volume with high-fidelity micromanometers. 31 In our study, the Vevo 770 HighResolution In Vivo Imaging System provided the measures of murine diastolic function. 19, 32 Mitral Doppler measurements are good measures of diastolic function in mice. 32 In a subset of mice, increased LVEDP correlated with an increased E/A ratio (data not shown). SBP control and LVH regression improve LV diastolic filling 33 ; however, LVH regression was not seen in our study. Once again, it is possible that, if mice were followed for an extended period, SBP control with HISDN and improved diastolic dysfunction may precede potential reductions in cardiac mass. 6 Equally plausible is that a delay in measurable change in structure may allow functional changes to precede structural changes.
HISDN and Cardiac Remodeling
Controversy surrounds the roles of LVH and HF. LVH regression, an intermediary between hypertension and HF, 6 may prevent both systolic and diastolic HFs. Conversely, although LVH increases the risk of HF, hypertensive subjects without LVH may also develop HF, 1 suggesting that targeting LVH may be unnecessary to prevent HF. The effect of LVH regression on diastolic dysfunction, one of the earliest changes in hypertension, is unclear. Even in the absence of LVH, SBP control improves diastolic filling irrespective of the regimen used. 6 It is unclear why LVH regression was not seen in the present study, but this indicates that LVH and hypertension may not have a causal relationship in this model. Furthermore, study duration may have been insuffi- cient; however, other experimental models with other therapies have shown LVH regression within 4 weeks. 34, 35 AHeFT suggested that chronic HISDN mediated positive effects on the myocardium. 17, 23 NO exerts beneficial effects on the vasculature, 15, 36 lowers SBP, 37 and also has direct effects on cardiac remodeling, 11 partly by increasing endothelial NO synthase and inhibiting LVH. [11] [12] [13] In our study, aldosterone induced LVH and diastolic HF, 18 and NO given in the form of ISDN was ineffective in reducing LVH or cardiomyocyte size despite SBP reduction. The form in which NO is given is important 38, 39 : uncoupled NO synthase (seen in hypertension, ischemia-reperfusion injury, and LVH with chamber remodeling 38 ) generates oxygen free radicals and less NO, shifts the nitroso-redox balance, and all may contribute to the development of diastolic dysfunction. Hydralazine also lowers SBP 40 and suppresses reactive oxygen species production 15 (which mediates cardiac hypertrophy 41 ). The addition of hydralazine to NO should theoretically shift the nitroso-redox balance (although not tested in our study) and result in LVH regression.
The persistence of LVH with HISDN in our study may be an adverse finding. Cardiac fetal gene re-expression, that is, upregulation of ANP and downregulation of SERCA2, is a marker of pathological remodeling. Because LVH persisted, we expected no change in myocardial ANP expression. However, both ANP and SERCA2 transcripts were decreased. It has been suggested that the development of LVH can, in part, be dissociated from activating the fetal gene program. 42, 43 Others have shown that an abnormal structural phenotype may exits without fetal gene expression but can coexist with molecular signaling pathways that ultimately lead to an abnormal phenotype. 44 Therefore, although speculative, HISDN may modulate gene expression and control signal transduction pathways involved in cardiac remodeling and diastolic dysfunction but may not modulate the cardiac phenotype. Our study does not exclude the possibility that reduced ANP expression may precede the eventual reduction in LVH if the animals had been followed for a longer time period.
Myocardial Fibrosis and Extracellular Matrix Remodeling
Myocardial fibrosis is closely related to diastolic stiffness. 45 Aldosterone-induced fibrosis was unaltered by HISDN, but collagen and matrix metalloproteinases were not measured. It has been suggested that total collagen is unaltered in diastolic dysfunction. 46 Posttranslational modification of myocardial collagen occurs, and local formation of advanced glycation end products-collagen links correlate with LV stiffness. 46 Myocardial fibrosis may contribute equally to LVH in diastolic HF. In the present study, HISDN had negligible effects on the extracellular "milieu" of the aldosterone-infused myocardium despite improvements in the E/A ratio. Thus, neither a reduction in myocardial fibrosis nor a decrease in LVH contributed to the improved diastolic dysfunction seen in aldosterone-induced diastolic HF, suggesting possible "extramyocardial" effects, such as a reduction in vascular inflammation.
HISDN and Cytokines
Myocardial interferon-␥, IL-6, and TNF-␣ expressions were increased in hypertension-induced diastolic HF. HISDN only decreased interferon-␥ and IL-6 expression. Chronic NO (with HISDN) may directly reduce interferon-␥ and IL-6 expression, or these decreased cytokines may simply reflect improved diastolic function. IL-6 has been shown to be prohypertrophic. 47 It is interesting that TNF-␣ expression remains unaffected by HISDN. It may be that concurrent TNF-␣ expression and the presence of myocardial NO may foster self-sustaining positive autocrine/paracrine feedback inflammatory circuits in diastolic HF. 48 
HISDN and Vascular Inflammation
Vascular inflammation, as reflected by sVCAM-1 levels, was elevated in hypertensive, aldosterone-infused mice. sVCAM levels were decreased with HISDN. In humans, sVCAM-1 is significantly associated with asymmetrical dimethylarginine, 49 an important endogenous NO synthase inhibitor. Similarly, NO synthesis inhibition is associated with an increase in endothelial adhesion molecule expression. 50 Thus, HISDN likely exerts beneficial effects on the vasculature.
Limitations
First, previous experimental studies using combination NO and hydralazine measured only acute hemodynamic effects. 14, 15 There are no human or animal studies that address the effect of combined HISDN (which is used clinically) on diastolic dysfunction and diastolic HF either acutely or chronically. Second, few animal models can successfully replicate human diastolic disease, and a single-cell study is limited in its inability to mimic diastolic disease given the importance of the vasculature (in preload and afterload), heart rate, chamber geometry, and extracellular matrix in diastology. Therefore, this model of hypertension-induced diastolic HF is a clinically relevant model. It encompasses the myocardium, potential effects of the vasculature, and exercise impairment. Third, although Millar catheterization was not performed in all of the mice, LVEDP correlated with the E/A ratio. Echocardiography allowed us to follow the mice longitudinally. Fourth, this study was performed exclusively in male mice. The prevalence of diastolic HF is greatest in elderly female mice. 32 A future study proposes to study aged, female mice. Finally, although not directly addressed in the present study, our findings suggests that HISDN effects were not limited exclusively to the myocardium, and the improvements seen were likely attributed to effects on the vasculature and interactions of vascular and ventricular stiffness. Our findings represent not so much a change in diastolic function as a change in myocardial load induced by alterations in vascular inflammation and/or stiffness because of HISDN.
In conclusion, HISDN did not prevent the progression to LVH or diastolic HF. LVH regression is unnecessary for the improvement in exercise capacity and diastolic dysfunction in hypertension. It is possible that improvement in ventricular inflammation/stiffness results in enhanced diastolic function and will require further study.
Perspectives
Diastolic dysfunction may precede the development of LVH in hypertension and is the connection between hypertension and diastolic HF. Although a lack of therapies continues to plague diastolic HF patients, understanding mechanisms primarily responsible for this clinical syndrome and its relationship to hypertension and diastolic dysfunction is important. Unlike human systolic HF studies, 17 our findings indicate that HISDN does not exert direct myocardial effects but rather influences ventricular-vascular interactions in diastolic HF. Additional studies are warranted to determine whether LVH regression is beneficial in hypertension-mediated diastolic dysfunction and to determine causality in diastolic dysfunction and cardiac remodeling.
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